Details of the Drug
General Information of Drug (ID: DMET46F)
Drug Name |
3,5-Difluorobenzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3,5-DIFLUOROBENZENESULFONAMIDE; 140480-89-3; 3,5-Difluorobenzenesulphonamide; Benzenesulfonamide, 3,5-difluoro-; 3,5-difluorobenzene-1-sulfonamide; Buttpark 27\07-04; FBU; PubChem11783; ACMC-20ai3d; AC1L9JFC; KSC493S5P; SCHEMBL602631; CHEBI:42566; CTK3J3957; DTXSID20332219; MKQPOVUFDWKPNO-UHFFFAOYSA-N; MolPort-000-150-739; ZINC2576766; JRD-1790; MFCD02091379; BBL100443; 6828AA; STL554237; ANW-74375; SBB091558; 3,5-Difluorobenzenesulfonamide, 97%; AKOS000148222; DB02087; VZ25762; TRA0083487; PS-8315; MCULE-4003409613; RTR-005258; CJ-10108
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 193.17 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||